Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant acinetobacter baumannii strains

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1622-1629

  Gopal, Ramamourthy ^a   Kim, Young Gwon ^a   Lee, Jun Ho ^a   Lee, Seog Ki ^a   Chae, Jeong Don ^b   Son, Byoung Kwan ^b   Seo, Chang Ho ^c   Park, Yoonkyung ^a  

^a Chosun University   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Kongju National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARBAPENEM; CEFOTAXIME; CIPROFLOXACIN; COLISTIN; ERYTHROMYCIN; IMIPENEM; POLYPEPTIDE ANTIBIOTIC AGENT; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATION; BIOFILM; CHIMERA; CHOLELITHIASIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CEFOTAXIME; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; KERATINOCYTES; KETOLIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84896875852     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02473-13     Document Type: Article

References (61)

1. Bergogne-Berezin E, Towner KJ. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165. (Pubitemid 26123943)
2. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
3. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. 2002. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J. Clin. Microbiol. 40:685-686. http://dx.doi.org/10. 1128/JCM.40.2.685-686.2002. (Pubitemid 34130907)
4. Giamarellou H, Antoniadou A. 2001. Antipseudomonal antibiotics. Med. Clin. N. Am. 85:19-41. http://dx.doi.org/10.1016/S0025-7125(05)70303-5.
5. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. 2008. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 3:649-660. http://dx.doi.org/10.2217/17460913.3.6.649.
6. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359. http://dx.doi.org/10.1128/JCM. 01284-07. (Pubitemid 47585661)
7. Fjell CD, Hiss JA, Hancock RE, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11:37-51. http://dx.doi.org/10.1038/nrd3591.
8. de la Fuente-Núñez C, Korolik V, Bains M, Nguyen U, Breidenstein EB, Horsman S, Lewenza S, Burrows L, Hancock RE. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob. Agents Chemother. 56:2696-2704. http://dx.doi.org/10.1128/AAC.00064-12.
9. Rodriguez-Hernandez MJ, Saugar J, Docobo-Perez F, de la Torre BG, Pachon-Ibanez ME, Garcia-Curiel A, Fernandez-Cuenca F, Andreu D, Rivas L, Pachon J. 2006. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 58:95-100. http://dx.doi.org/10.1093/jac/dkl145. (Pubitemid 44294991)
10. 2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 24:1315-1318. http://dx.doi.org/10.1016/j.peptides.2003.08.003.
11. Saugar JM, Alarcón T, López-Hernández S, López-Brea M, Andreu D, Rivas L. 2002. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob. Agents Chemother. 46:875-878. http://dx.doi.org/10.1128/AAC.46.3.875-878.2002. (Pubitemid 34157679)
12. Saugar JM, Rodriguez-Hernandez MJ, de la Torre BG, Pachon-Ibanez ME, Fernandez-Reyes M, Andreu D, Pachon J, Rivas L. 2006. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob. Agents Chemother. 50:1251-1256. http://dx.doi.org/10.1128/ AAC.50.4.1251-1256.2006.
13. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG. 1981. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292:246-248. http://dx.doi.org/10.1038/292246a0. (Pubitemid 11001840)
14. Macias EA, Rana F, Blazyk J, Modrzakowski MC. 1990. Bactericidal activity of magainin 2: use of lipopolysaccharide mutants. Can. J. Microbiol. 36:582-584. http://dx.doi.org/10.1139/m90-102. (Pubitemid 20350408)
15. Cuervo JH, Rodriguez B, Houghten RA. 1988. The magainins: sequence factors relevant to increased antimicrobial activity and decreased hemolytic activity. Pept. Res. 1:81-86.
16. Silvestro L, Axelsen PH. 2000. Membrane-induced folding of cecropin A. Biophys. J. 79:1465-1477. http://dx.doi.org/10.1016/S0006-3495(00)76398-3.
17. Boman HG. 1991. Antibacterial peptides: key components needed in immunity. Cell 65:205-207. http://dx.doi.org/10.1016/0092-8674(91)90154-Q. (Pubitemid 121006052)
18. Boman HG. 1995. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13:61-92. http://dx.doi.org/10.1146/annurev.iy.13.040195. 000425.
19. Zasloff M. 1987. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. U. S. A. 84:5449-5453. http://dx.doi.org/10.1073/pnas.84.15.5449. (Pubitemid 17129018)
20. Putsep K, Brändén CI, Boman HG, Normark S. 1999. Antibacterial peptide from H. pylori. Nature 398:671-672. http://dx.doi.org/10. 1038/19439.
21. Tosteson MT, Holmes SJ, Razin M, Tosteson DC. 1985. Melittin of a red cells. J. Membr. Biol. 87:35-44. http://dx.doi.org/10.1007/BF01870697.
22. Selsted ME. 1997. HPLC methods for purification of antimicrobial peptides. Methods Mol. Biol. 78:17-33.
23. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne. PA.
24. Jeong N, Kim JY, Park SC, Lee JK, Gopal R, Yoo S, Son BK, Hahm JS, Park Y, Hahm KS. 2010. Antibiotic and synergistic effect of Leu-Lys rich peptide against antibiotic resistant microorganisms isolated from patients with cholelithiasis. Biochem. Biophys. Res. Commun. 399:581-586. http://dx.doi.org/ 10.1016/j.bbrc.2010.07.118.
25. Dawis MA, Isenberg HD, France KA, Jenkins SG. 2003. In vitro activity of gatifloxacin alone in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J. Antimicrob. Chemother. 51:1203-1211. http://dx.doi.org/10.1093/jac/dkg238. (Pubitemid 36622076)
26. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH. 1985. Adherence of coagulase-negative staphylococci to plastic tissue culture plate: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 22:996-1006. (Pubitemid 16222727)
27. Hwang IS, Hwang JS, Hwang JH, Choi H, Lee E, Kim Y, Lee DG. 2013. Synergistic effect and antibiofilm activity between the antimicrobial peptide coprisin and conventional antibiotics against opportunistic bacteria. Curr. Microbiol. 66:56-60. http://dx.doi.org/10.1007/s00284-012-0239-8.
28. Wei GX, Campagna AN, Bobek LA. 2006. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J. Antimicrob. Chemother. 57:1100-1109. http://dx.doi.org/10.1093/jac/dkl120. (Pubitemid 44644411)
29. Gopal R, Lee JH, Kim YG, Kim MS, Seo CH, Park Y. 2013. Antimicrobial, anti-biofilm activities and cell selectivity of the NRC-16 peptide derived from witch flounder, Glyptocephalus cynoglossus. Mar. Drugs 11:1836-1852. http://dx.doi.org/10.3390/md11061836.
30. Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS, Chopade BA. 2011. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol. Med. Microbiol. 62:328-338. http://dx.doi.org/10.1111/j.1574-695X.2011.00818.x.
31. Crane DP, Gromov K, Li D, Søballe K, Wahnes C, Büchner H, Hilton MJ, O'Keefe RJ, Murray CK, Schwarz EM. 2009. Efficacy of colistin-impregnated beads to prevent multidrug-resistant A. baumannii implantassociated osteomyelitis. J. Orthop. Res. 27:1008-1015. http://dx.doi.org/10.1002/jor.20847.
32. Rodríguez-Baño J, Martí S, Soto S, Fernández-Cuenca F, Cisneros JM, Pachón J, Pascual A, Martínez-Martínez L, McQueary C, Actis LA, Vila J. 2008. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin. Microbiol. Infect. 14:276-278. http://dx.doi.org/10.1111/j. 1469-0691.2007.01916.x. (Pubitemid 351201019)
33. Kempf M, Rolain JM. 2012. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. Agents 39:105-114. http://dx.doi.org/10.1016/j.ijantimicag.2011. 10.004.
34. Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. 2013. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev. Anti Infect. Ther. 11:395-409. http://dx.doi.org/10.1586/eri.13.21.
35. Lim YM, Shin KS, Kim J. 2007. Distinct antimicrobial resistance patterns and antimicrobial resistance-harboring genes according to genomic species of Acinetobacter isolates. J. Clin. Microbiol. 45:902-905. http://dx.doi.org/10. 1128/JCM.01573-06. (Pubitemid 46427709)
36. Simor AE, Lee M, Vearncombe M, Jones-Paul L, Barry C, Gomez M, Fish JS, Cartotto RC, Palmer R, Louie M. 2002. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect. Control Hosp. Epidemiol. 23:261-267. http://dx.doi.org/10. 1086/502046. (Pubitemid 34525269)
37. Vahaboglu H, Ozturk R, Aygun G, Coskunkan F, Yaman F, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M. 1997. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. 41:2265-2269. (Pubitemid 27422224)
38. Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, Chong Y, Bauernfeind. 2003. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob. Agents. Chemother. 47:1749-1751. http://dx.doi.org/10.1128/AAC.47.5.1749-1751.2003.
39. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. 2007. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 45:594-598. http://dx.doi.org/10.1086/520658. (Pubitemid 47328640)
40. Calandra T. 2001. Pathogenesis of septic shock: implications for prevention and treatment. J. Chemother. 13:173-180. (Pubitemid 34183612)
41. David SA, Awasthi SK, Balaram P. 2000. The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. J. Endotoxin Res. 6:249-256. http://dx.doi.org/10. 1177/09680519000060030601.
42. Guerra AN, Fisette PL, Pfeiffer ZA, Quinchia-Rios BH, Prabhu U, Aga M, Denlinger LC, Guadarrama AG, Abozeid S, Sommer JA, Proctor RA, Bertics PJ. 2003. Purinergic receptor regulation of LPS-induced signaling and pathophysiology. J. Endotoxin Res. 9:256-263. http://dx.doi.org/10.1179/096805103225001468. (Pubitemid 36874537)
43. Hancock REW, Lehrer R. 1998. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16:82-88. http://dx.doi.org/10.1016/S0167- 7799(97)01156-6. (Pubitemid 28055477)
44. Shin SY, Lee MK, Kim KL, Hahm KS. 1997. Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. 50:279-285. (Pubitemid 27440877)
45. Park Y, Lee DG, Hahm KS. 2004. HP(2-9)-magainin 2(1-12), a synthetic hybrid peptide, exerts its antifungal effect on Candida albicans by damaging the plasma membrane. J. Pept. Sci. 10:204-209. http://dx.doi.org/10.1002/psc.489. (Pubitemid 38515003)
46. Shi Y, Cromie MJ, Hsu FF, Turk J, Groisman EA. 2004. PhoP-regulated Salmonella resistance to the antimicrobial peptides magainin 2 and polymyxin B. Mol. Microbiol. 53:229-241. http://dx.doi.org/10.1111/j.1365-2958.2004.04107.x. (Pubitemid 38901393)
47. Guina T, Yi EC, Wang H, Hackett M, Miller SI. 2000. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J. Bacteriol. 182:4077-4086. http://dx.doi.org/10.1128/JB.182.14.4077-4086.2000. (Pubitemid 30436571)
48. Abi Khattar Z, Rejasse A, Destoumieux-Garzon D, Escoubas JM, Sanchis V, Lereclus D, Givaudan A, Kallassy M, Nielsen-Leroux C, Gaudriault S. 2009. The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects. J. Bacteriol. 191:7063-7073. http://dx.doi.org/10.1128/JB.00892-09.
49. Alarcón T, López-Hernández S, Andreu D, Saugar JM, Rivas L, López-Brea M. 2001. In vitro activity of CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide, against multiresistant Acinetobacter baumannii strains. Rev. Esp. Quimioter. 14:184-190. (Pubitemid 32743782)
50. Sands M, McCarter Y, Sanchez W. 2007. Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E test methodology. Eur. J. Clin. Microbiol. Infect. Dis. 26:521-522. http://dx.doi.org/10.1007/s10096-007-0330-4. (Pubitemid 47025046)
51. Tan TY, Ng LSY, Tan E, Huang G. 2007. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumanii clinical isolates. J. Antimicrob. Chemother. 60:421-423. http://dx.doi.org/10.1093/jac/ dkm178. (Pubitemid 47243898)
52. Yoon J, Urban C, Terzian N, Mariano N, Rahal J. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-757. http://dx.doi.org/10.1128/AAC.48.3.753-757.2004. (Pubitemid 38280320)
53. Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, Prashanth K. 2008. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J. Med. Microbiol. 26:333-337. http://dx.doi.org/10.4103/0255-0857.43566.
54. de Breij A, Haisma EM, Rietveld M, El Ghalbzouri A, van den Broek PJ, Dijkshoorn L, Nibbering PH. 2012. Three-dimensional human skin equivalent as a tool to study Acinetobacter baumannii colonization. Antimicrob. Agents Chemother. 56:2459-2464. http://dx.doi.org/10.1128/AAC.05975-11.
55. Ehrenstein B, Bernards AT, Dijkshoorn L, Gerner-Smidt P, Towner KJ, Bouvet PJ, Daschner FD, Grundmann H. 1996. Acinetobacter species identification by using tRNA spacer fingerprinting. J. Clin. Microbiol. 34:2414-2420. (Pubitemid 26307783)
56. Joly-Guillou ML. 2005. Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11:868-873. http://dx.doi.org/10.1111/j. 1469-0691.2005.01227.x.
57. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, Martínez-Martínez L, Bou G, Pachón J. 2004. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect. Control Hosp. Epidemiol. 25:819-824. http://dx.doi.org/10.1086/502302. (Pubitemid 40036756)
58. Huang XQ, Xiang J, Song F, Huan JN. 2012. Effects of topical agents for burns on Acinetobacter baumannii within biofilm. Zhonghua ShaoShang ZaZhi 28:106-110.
59. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for management of multidrug resistant gram negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. http://dx.doi.org/10.1086/429323. (Pubitemid 40570245)
60. Feng X, Sambanthamoorthy K, Palys T, Paranavitana C. 2013. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides 49:131-137. http://dx.doi.org/10.1016/j.peptides.2013.09.007.
61. López-Rojas R, Docobo-Pérez F, Pachón- Ibáñez ME, de la Torre BG, Fernández-Reyes M, March C, Bengoechea JA, Andreu D, Rivas L, Pachón J. 2011. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 30:1391-1398. http://dx.doi.org/10.1007/s10096-011-1233-y.